Real-World data reveals how breast cancer patients actually use CDK4/6 drugs
NCT ID NCT07512063
First seen Apr 11, 2026 · Last updated May 03, 2026 · Updated 4 times
Summary
This study looked at 480 patients with a common type of advanced breast cancer (HR+, HER2-) who were treated with a class of drugs called CDK4/6 inhibitors. Researchers wanted to understand patient characteristics, treatment patterns, and outcomes in everyday medical practice, not just in controlled trials. The goal was to gather information to help doctors make better treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.